First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

Minami Omura; Takeo Kosaka; Eriko Aimono; Kohei Nakamura; Hiroshi Hongo; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya

doi:10.1002/iju5.12383

First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

Minami Omura, Takeo Kosaka, Eriko Aimono, Kohei Nakamura, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

Original language	English
Pages (from-to)	41-44
Number of pages	4
Journal	IJU Case Reports
Volume	5
Issue number	1
DOIs	https://doi.org/10.1002/iju5.12383
Publication status	Published - 2022 Jan

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/iju5.12383

Cite this

@article{97050398452a48d7bc52f6074a6e78f4,

title = "First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations",

abstract = "Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.",

author = "Minami Omura and Takeo Kosaka and Eriko Aimono and Kohei Nakamura and Hiroshi Hongo and Shuji Mikami and Hiroshi Nishihara and Mototsugu Oya",

note = "Funding Information: This work was supported in part by a Grant‐in‐Aid for Scientific Research (B: #20H03817 to TK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The work was supported in part by a research grant to T. Kosaka from Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research, Japan. Publisher Copyright: {\textcopyright} 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association",

year = "2022",

month = jan,

doi = "10.1002/iju5.12383",

language = "English",

volume = "5",

pages = "41--44",

journal = "IJU Case Reports",

issn = "2577-171X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

AU - Omura, Minami

AU - Kosaka, Takeo

AU - Aimono, Eriko

AU - Nakamura, Kohei

AU - Hongo, Hiroshi

AU - Mikami, Shuji

AU - Nishihara, Hiroshi

AU - Oya, Mototsugu

N1 - Funding Information: This work was supported in part by a Grant‐in‐Aid for Scientific Research (B: #20H03817 to TK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The work was supported in part by a research grant to T. Kosaka from Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research, Japan. Publisher Copyright: © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association

PY - 2022/1

Y1 - 2022/1

N2 - Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

AB - Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

UR - http://www.scopus.com/inward/record.url?scp=85117344726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117344726&partnerID=8YFLogxK

U2 - 10.1002/iju5.12383

DO - 10.1002/iju5.12383

M3 - Article

AN - SCOPUS:85117344726

SN - 2577-171X

VL - 5

SP - 41

EP - 44

JO - IJU Case Reports

JF - IJU Case Reports

IS - 1

ER -

First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this